Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Shortened p53 Protein Promotes Tumor Growth by Modulating Mitochondrial Function

By LabMedica International staff writers
Posted on 20 Dec 2016
A shortened version of the p53 protein - caused by a mutation in the TP53 tumor suppressor gene – has been found to promote rather than impede tumor growth.

The gene that encodes p53 is the most frequently mutated gene found in many types of cancer, and notably in most late-stage cancers. More...
While most p53 gene mutations prevent p53 from being functional, investigators at Cold Spring Harbor Laboratory (NY, USA) discovered a variety of mutated p53 protein that actually promoted tumor growth.

The investigators reported in the October 19, 2016, online edition of the journal eLife that p53 proteins truncated after the sixth protein-coding segment (exon-6) no longer functioned as tumor suppressors but instead promoted cancer by directly altering the functions of mitochondria. The version of p53 encoded by TP53 exon-6 truncating mutations lacked roughly half of the domains of the full-length p53 protein, specifically the domains that enable full-length p53 to enter the cell nucleus and bind DNA.

TP53 exon-6 truncating mutations occurred at higher than expected frequencies and produced proteins that lacked canonical p53 tumor suppressor activities but instead promoted cancer cell proliferation, survival, and metastasis. Functionally and molecularly, these p53 mutants resembled the naturally occurring alternative p53 splice variant, p53-psi. Due to their similarity to p53-psi, these mutants were able to localize to the mitochondria where they promoted tumor phenotypes by binding and activating the mitochondria inner pore permeability regulator protein, Cyclophilin D (CypD).

"Remarkably, despite 40 years of research and over 80,000 publications on p53, our new findings show that it still holds mystery and promise," said senior author Dr. Raffaella Sordella, an associate professor at Cold Springs Harbor Laboratory. "It seems that by changing mitochondrial function, the variants are priming cells to reprogram themselves. These mutations are strong candidates for targeting by precision medicine. The frequency of exon-6 truncating mutations in fact is comparable to other precision medicine targets such as the EGFR oncogenic-mutations found in lung cancer. We have begun discussing with several pharmaceutical companies ways in which we can use our newly gained knowledge to develop treatments that will make a positive difference for many cancer patients."

Related Links:
Cold Spring Harbor Laboratory



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.